Insider Transactions in Q1 2021 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,330
+50.0%
|
$0
$0.84 P/Share
|
|
Mar 16
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-5.48%
|
$36,000
$45.0 P/Share
|
|
Mar 16
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.19%
|
$5,600
$7.26 P/Share
|
|
Mar 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-26.5%
|
$82,000
$41.84 P/Share
|
|
Mar 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+41.62%
|
$2,000
$1.86 P/Share
|
|
Mar 08
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-77.73%
|
$277,500
$37.38 P/Share
|
|
Mar 08
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$0
$0.84 P/Share
|
|
Mar 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-5.48%
|
$28,000
$35.95 P/Share
|
|
Mar 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.19%
|
$5,600
$7.26 P/Share
|
|
Feb 24
2021
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
35,419
-100.0%
|
$1,381,341
$39.9 P/Share
|
|
Feb 24
2021
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,419
+27.71%
|
$106,257
$3.44 P/Share
|
|
Feb 22
2021
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,330
-100.0%
|
$207,870
$39.93 P/Share
|
|
Feb 22
2021
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,330
+46.17%
|
$5,330
$1.02 P/Share
|
|
Feb 18
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
15,000
-61.6%
|
$540,000
$36.0 P/Share
|
|
Feb 18
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+28.33%
|
$75,000
$5.89 P/Share
|
|
Feb 18
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-3.16%
|
$28,800
$36.74 P/Share
|
|
Feb 18
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.88%
|
$5,600
$7.26 P/Share
|
|
Feb 18
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-62.92%
|
$70,000
$35.79 P/Share
|
|
Feb 18
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$2,000
$1.86 P/Share
|
|
Feb 18
2021
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,583
-60.97%
|
$488,988
$36.06 P/Share
|
|
Feb 18
2021
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,583
+50.0%
|
$0
$0.84 P/Share
|
|
Feb 04
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
914,216
-16.86%
|
-
|